The determined IL-21/IL-22 ratio, both at the mRNA level in the tissue and at the protein level in the serum and in the peritoneal fluid in patients with ovarian cancer, showed a variable share of the tested cytokines in the IL-21/IL-22 system, depending on the histological differentiation of the cancer. The gene discussed is IL22; the disease is ovarian carcinoma.